8
edits
Changes
Jump to navigation
Jump to search
Line 1:
Line 1: + + + + + + + + + + + + + − + − + − + + + + + + Line 11:
Line 29: + + + + + + + + + + + + + + + + − + − + + + + + + + − + − + + + + + − + − | ||+ + + + + − + − | ||+ + + + + + − + − + + + + + + − + − | ||+ + + + + + − + − | ||+ + + + + + − + − + + + + + + − + − | ||+ + + + + + + + + + − + − | ||+ + + + + + − + − | ||+ + + + + + − + − | ||+ + + + + − + − | ||+ + + + + + − + − + + + + + + − + − + + + + + + − + − + + + + + − + − + + + + + − + − + + + + + − + − | ||+ + + + + + − + − | ||+ + + + + + − + − | ||+ + + + + + − + − + + + + + + − + − + + + + + + − + − | ||+ + + + + + − + − | ||+ + + + + + − + − | ||+ + + + + + + + + + + + + + − + − + − + − |Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR||+ − | ||+ − + − + − | ||+ − + − + − + − + − + − | ||+ − |-+ − |Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| − | || + + + + + + + + + + + + + + + + + + + + − + − + − + + + + + − + − + Line 148:
Line 341: + + + + − + − + Line 161:
Line 358: + + + + − + + + + + + + + + + + + + + + + + Line 173:
Line 390: − + + + + + − + − + Line 185:
Line 406: + + + + − + − + Line 196:
Line 421: + + + + − + − + Line 208:
Line 437: + + + + − + Line 221:
Line 454: − + + + + + − + + + − |JH_MS + + + − + − + Line 244:
Line 485: + + + + − + − + Line 256:
Line 501: + + + + − + − + Line 268:
Line 517: + + + + − + + + − |JH_MS + + + − + − + Line 292:
Line 549: + + + + − + − + Line 304:
Line 565: + + + + − + − + Line 316:
Line 581: + + + + − + − + Line 328:
Line 597: + + + + − + + + + + + + + + + + + + + + + + + + + − + Line 341:
Line 633: + + + + − + − + Line 353:
Line 649: − + + + + + − + − + Line 364:
Line 664: + + + + − + − + − + + + + + − + − + + + − |JH_MS + + + − + − + + + − |JH_MS + + + − + + + + + + + + + + + + + + + + + + + − |JH_MS + + + + + + − + − |Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO − |JH_MS + + + + + + − + − |Tracy Tucker, PhD, FCCMG − |JH_MS + + + + + + − + + + + + + + + + + + + + + + + + + + + + − + Line 461:
Line 828: − + + + + + − + − + Line 472:
Line 843: + + + + − + − + Line 484:
Line 859: + + + + − + − + Line 496:
Line 875: + + + + − + Line 509:
Line 892: − + + + + + − + − + Line 521:
Line 908: + + + + + + + + + + + + + + + − |-+ − |CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS) Line 541:
Line 942: + + + + Line 546:
Line 951: + + + + + + − + + − + − |JH_MS + + + + − + − + + + − |JH_MS + + + + + + + + + − |- + + + + + + + + + Line 582:
Line 1,015: + + + + + + + + + + + + + + + + + + Line 596:
Line 1,047: + + + + + + + + + + + + + + + + + + + + + + Line 606:
Line 1,079: + + + + + + + + + + + + + + + + + + + + + + + + + + Line 627:
Line 1,126: + + + + + + + + + − |-+ − |CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) Line 641:
Line 1,148: + + + + Line 646:
Line 1,157: + + + + + + − + + + + + + − ----<br />+ − ----<br /> + + + + + + + + Line 660:
Line 1,189: + + + + + + − + + + + − ----<br /> − ----<br /> + + + + + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − + + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − + + + + + + + + + + + + + + − + − + + + + + + + + + + + + + + − + − | ||+ − |-+ − |Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC||+ − | ||+ − |-+ − |T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC||+ − | ||+ − |-+ − |Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC||+ − | ||+ − |-+ − |ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC||+ − | ||+ − + − |Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| − | || − − − | || − − − | || − |- − |EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| − | || − |- − |Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| − | || − |- − − | || − |- − |Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| − | || − |- − |Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| − − |- − |Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| − | || − |- − |Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| − | || − |- − |Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| − | || − |- − |Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| − | || − − |Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| − | || − |- − |High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| − | || − |- − |Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| − − |- − |Primary effusion lymphoma||Disease|| || || || || ||GC|| − | || − |- − |KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| − | || − |- − |KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| − | || − |- − |Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| − | || − |- − |Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| − | || − |- − |EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| − | || − |- − |Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| − | || − |- − |Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| − | || − |- − |Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| − | || − |- − |Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| − | || + + + + + + Line 814:
Line 1,468: + − + + + + + + + − + − + + + + + + + + + + − + − + + + + + + − + − + + + + + + − + − + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + + + − + − + + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − + − + − | || || || || || || || ||+ − | ||+ − + − | || || || || || || || ||+ − | ||+ − + − | || || || || || || || ||+ − | ||+ − + − + − + − + − | || || || || || || || || − | || − |- − | || || || || || || || || − | || − |- − | || || || || || || || || − | || − |- − | || || || || || || || || − | || − |- − | || || || || || || || || − | || + + + + + + + + + + + + + + + + + + + + − + − | ||+ − |-+ − | || || || || || || || ||+ − | || − − − | || − − − | || − |- − | || || || || || || || || − | || − |- − | || || || || || || || || − | || − |- − | || || || || || || || || − | || − |- − | || || || || || || || || − | || − |- + + + + + + + + + Line 939:
Line 1,751: + + + + + + + − + − + + + + + + − + − + + + + + − + − + + + + + + − + − + + + + + + − + − + + + + + + − + − + + + + + + − + − + + + + + − + − + + + + + + − + − + − + − + − + + − + − + + + + + + − + − + + + + + − + − + + + + + + − + − + + + + + + − + − + + + + + − + − + + + + + + − + − + + + + + − + − + + + + + − + − + + + + + + − + − + + + + + + − + − + + + + + − + − + + + + + − + − + + + + + − + − + + + + + − + − + + + + + + + − + − + + + + + − + − + + + + + − + − + + + + + − + − + + + + + + + − + − + + + + + − + − + + + + + + + + + + + + + + − + − + + + + + − + − + + + + + − + + + + + + − + + + + + + + − + + + + + + + − + + + + + + − + + + + + + + − + + + + + + − + − + + + + + + + + − + − + + + + + + + − + − + + + + + + + + − |Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SP||+ − + + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + + + + + + + + + + + + + + + − + + + + + + − + − + + + + + + + − + − + + + + + − + − + + + + + − + − | ||+ + + + + + + + + + + + + + − + − + + + + + + + + + + + + + + + − + − + + + + + + + + + − + − + + + + + + + + + + − + − + + + + + + − + − + + + + + + + − + − + + + + + + − + − + + + + + + + + − + − + + + + + + + + + + − + − + + + + + + + − + − + + + + + − + − + + + + + + − + − + + + + + + + + − + − + + + + + + − + − + + + + + + + + + − + − + + + + + − + − + + + + + + − + − + + + + + − + − + + + + + + + + − + − + + + + + + + + − + − + + + + + + − + − + + + + + + + + + + − + − + + + + + + + + + + + + + − + − + + + + + + + + − + − + + + + + + + − + − + + + + + + − + − + + + + + + − + − + + + + + + − + − + + + + + + + − + − + + + + + − + − + + + + + + + + − + − + + + + + − + − + + + + + − + − + + + + + + + − + − + + + + + + + − + − | ||+ + + + + + + + + + + + + + + + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + − + − + + + + + + + + + + + + + + − + − + + + + + + + + + + + + + + − + − + + + + + + + + + + + + + + − + − + + + + + + + + + + + + + + − + − + + + + + + + + + + + + + + − + − + + + + + + + + + + + + + + − + − | ||+ + + + + + + + + + + + + + + + + + + + + + + + + + + + − + − + + + + + − + − + − + − + − + + − + − + + + + + − + − + − + − + − + +
HAEM5:Volunteer Assignments and Opportunities (view source)
Revision as of 16:23, 16 April 2024
, 16:23, 16 April 2024Updated
Welcome!
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
*For assignments, please see the "Author" column below (highlighted blue).
*If empty (no name is present), please volunteer to create content for that disease!
*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
<br />
{| class="wikitable" style="margin:auto"
{| class="wikitable" style="margin:auto"
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
|-
|-
!Disease (5th Edition)!!Page Type!!Author!!Date Assigned to Author!!Target Completion Date!!Author Content (Pending or Complete)!!Date Completed by Author!!Associate Editor!!Date of Last Editor Review
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
!Correlated Prior Disease Name (4th Edition)!!Notes
!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
----<br />
----<br />
|
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)||
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
| ||
|4/8/24
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR||
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease|| || || || || ||FQR|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR||
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Complete
|Date page was created
|
|-
|-
|Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally|| || || || ||FQR||
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Neutrophilic Leukemia (CNL)
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally
|Complete
|Date page was created
|
|-
|-
|Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff Pending Review*|| || || || ||FQR||
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING
| ||
| || || || ||FQR|| ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chelsea D. Kramish; Daynna J.Wolff
|complete/pending faculty review
|
|
|-
|-
|Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center|| || || || ||FQR||
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING
| || || || ||FQR|| ||
|Polycythemia Vera (PV)
|Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center
|Complete
|
|
|-
|-
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR||
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Essential Thrombocythemia (ET)
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|Complete
|
|
|-
|-
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR||
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING
| ||
| || || || ||FQR|| ||
|Primary Myelofibrosis (PMF)
|T. Niroshi Senaratne, UCLA
|Complete
|8/4/2020 before submission<br />
|
|-
|-
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories|| || || || ||FQR||
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING
| || || || ||FQR|| ||
|Juvenile Myelomonocytic Leukemia (JMML)
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
Associate Director | Division of Molecular Pathology, Genetics and Genomics
Duke University Health System Clinical Laboratories
|PENDING importing content and reference formatting
|
|FQR has emailed SR several times, last 4/20/22
|-
|-
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR||
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING
| || || || ||FQR|| ||
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Thomas Lee, MD, PhD, University of California, Los Angeles
|Complete
|
|
|-
|-
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR||
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Cutaneous Mastocytosis
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
|Complete
|
|
|-
|-
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR||
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| ||
|Systemic Mastocytosis
|Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University
|Complete
|
|
|-
|-
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR||
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING
| || || || ||FQR|| ||
|Mast Cell Sarcoma
|Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL
|Complete
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING
| ||
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
|Complete
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING
| ||
| || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR||
|[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?)|| || || || ||FQR|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR||
|[[HAEM5:Myelodysplastic neoplasm with low blasts|Myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR||
|[[HAEM5:Myelodysplastic neoplasm, hypoplastic|Myelodysplastic neoplasm, hypoplastic]]||Disease|| || || || || ||FQR|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Complete
|
|
|-
|-
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Complete
|
|
|-
|-
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Complete
|
|
|-
|-
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR||
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING
| ||
| || || || ||FQR|| ||
|Chronic Myelomonocytic Leukemia (CMML)
|Linsheng Zhang, MD, PhD
|Complete
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING
| ||
| || || || ||FQR|| ||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Linsheng Zhang, MD, PhD
|Complete
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
|Complete
|Date page was created
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia|| || || || ||FQR||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia
|Complete
|
|
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR||
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
|Disease
|PENDING
|
|
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|
|
|Acute Promyelocytic Leukemia (APL) with PML-RARA
|Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D.
|Complete
|03/01/2021-MS (re-review)
|
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR||
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
| ||
|Disease
|-
|PENDING
|
|
|-
|
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR||
|
|JH_MS
|-
|
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR||
|
| ||
|Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
|-
|Christine Bryke, MD<br>Beth Israel Deaconess Medical Center, Boston, MA
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR||
|Complete
|04/26/2021-MS (re-review)
|
|-
|-
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
|Disease
|PENDING
|
|
|
|
|
|JH_MS
|
|
|
|
|Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
|Christine Bryke, MD <br> Beth Israel Deaconess Medical Center, Boston, MA
|Complete
|03/01/2021-MS (re-review)
|
|
|-
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
|Disease
|PENDING
|
|
|
|
|
|
|
|
|JH_MS
|
|
|
|
|Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214
|Jennelle C. Hodge, PhD, FACMG
|Complete
|02/24/2021-MS (re-review)
|
|
|-
|-
|Acute promyelocytic leukaemia with PML::RARA fusion
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
|Disease
|Disease
|Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D.
|PENDING
|
|
|
|
|
|
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|JH_MS
|
|
|
|Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1
|Jennelle C. Hodge, PhD, FACMG
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|Christine Bryke, MD<br>Beth Israel Deaconess Medical Center, Boston, MA
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Acute Myeloid Leukemia (AML) with BCR-ABL1
|Kay Weng Choy MBBS, Monash Medical Centre
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with CBFB::MYH11 fusion
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|Christine Bryke, MD <br> Beth Israel Deaconess Medical Center, Boston, MA
|PENDING
|
|
|
|
|
|
|
|
|Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3
|Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D.
|Complete
|03/01/2021-MS (re-review)
|
|
|-
|-
|Acute myeloid leukaemia with DEK::NUP214 fusion
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
|Disease
|Disease
|PENDING
|
|
|
|
|JH_MS
|
|
|
|Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
|Gordana Raca MD PhD, University of Southern California, Los Angeles
|Complete
|
|
|Need permission for figure? Update WHO?
|-
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
|Disease
|Eric McGinnis, MD
|12/20/23
|
|
|
|
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Acute myeloid leukaemia with RBM15::MRTFA fusion
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
|Disease
|Disease
|Jennelle C. Hodge, PhD, FACMG
|PENDING
|
|
|
|
|
|
|
|
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Xinjie Xu, PhD, FACMG
|Complete
|
|
|Add WHO reference
|-
|-
|Acute myeloid leukaemia with BCR::ABL1 fusion
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|Disease
|Disease
|Kay Weng Choy MBBS, Monash Medical Centre
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA
|Paul Defazio, MSc, Monash Health
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with KMT2A rearrangement
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
|Disease
|Disease
|Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D.
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with MECOM rearrangement
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
|Disease
|Disease
|
|
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Acute myeloid leukaemia with NUP98 rearrangement
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
|Disease
|Disease
|PENDING
|
|
|
|
|
|
|
|
|JH_MS
|
|
|
|
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with NPM1 mutation
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
|Disease
|Disease
|Xinjie Xu, PhD, FACMG
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Acute Myeloid Leukemia (AML) without Maturation
|Jennelle C. Hodge, PhD, FACMG
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with CEBPA mutation
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
|Disease
|Disease
|Paul Defazio, MSc, Monash Health
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Acute Myeloid Leukemia (AML) with Maturation
|Jennelle C. Hodge, PhD, FACMG
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia, myelodysplasia-related
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
|Disease
|Disease
|Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Acute Basophilic Leukemia
|Ashwini Yenamandra PhD FACMG
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with other defined genetic alterations
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
|Disease
|Disease
|PENDING
|
|
|
|
|
|
|
|
|JH_MS
|
|
|
|
|Acute Myelomonocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with minimal differentiation
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
|Disease
|Disease
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Acute Monoblastic and Monocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia without maturation
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
|Disease
|Disease
|Jennelle C. Hodge, PhD, FACMG
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Pure Erythroid Leukemia
|Ashwini Yenamandra PhD FACMG
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with maturation
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
|Disease
|Disease
|Jennelle C. Hodge, PhD, FACMG
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Acute Megakaryoblastic Leukemia (AMKL)
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Complete
|
|
|
|
|-
|-
|Acute basophilic leukaemia
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Myeloid Sarcoma
|Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine
|Complete
|
|
|
|
|-
|-
|Acute myelomonocytic leukaemia
|RESOLVE 4th edition AML-Related NON-WHO entities content
|[[HAEM4:Acute Myeloid Leukemia (AML) with Mutated FLT3|Acute Myeloid Leukemia (AML) with Mutated FLT3]] + [[HAEM4:Acute Myeloid Leukemia (AML) with NUP214-ABL1|Acute Myeloid Leukemia (AML) with NUP214-ABL1]] + [[HAEM4:Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6|Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6]]
|ISSUE- FIX
Resolve Non-WHO entities
|
|
|
|
|
|
|
|
|
|
|
|
|-
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
|Disease
|Disease
|Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR
|PENDING
|
|
|
|
|
|
|
|
|Therapy-Related Myeloid Neoplasms
|Shawn A. Silver, DO, Shashi Shetty, Ph.D.
|Complete
|
|
|Check reference format
|-
|-
|Acute monocytic leukaemia
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
|Disease
|Disease
|Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR
|PENDING
|
|
|
|
|
|
|
|
|
|Multiple pages including overview page ([[Myeloid Neoplasms with Germline Predisposition|Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)]]) and 6 disease pages ( [[HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation]], [[HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation]])
|See links from instructions on the 5th edition page
|Complete
|Most were re-reviewed by MS on 03/02/2021
|For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022"
|-
|-
|Acute erythroid leukaemia
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|Complete (all three pages)
|
|
|
|
|-
|-
|Acute megakaryoblastic leukaemia
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
|Disease
|Disease
|Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR
|PENDING
|
|
|
|
|
|
|
|
|JH_MS
|FQR
|
|
|
|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement
|Jay Alden, DO
|Complete
|
|
|
|
|-
|-
|Myeloid sarcoma
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
|Disease
|Disease
|Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine
|PENDING
|
|
|
|
|
|
|
|FQR
|
|
|
|
|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement
|Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD
|Complete
|
|
|
|
|-
|-
|Myeloid neoplasm post cytotoxic therapy
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
|Disease
|Disease
|Shawn A. Silver, DO, Shashi Shetty, Ph.D.
|PENDING
|
|
|
|
|
|
|
|FQR
|
|
|
|
|Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
|Yanna Ding, MD PhD
|Complete
|
|
|
|
|-
|-
|Myeloid neoplasms associated with germline predisposition
|[[HAEM5:Myeloid/lymphoid neoplasm with JAK2 rearrangement|Myeloid/lymphoid neoplasm with JAK2 rearrangement]]
|Disease
|Disease
|ISSUE- FIX
Resolve Non-WHO entities
|
|
|
|
|FQR
|
|
|Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with ETV6-JAK2|Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]]) + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with BCR-JAK2|Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]] ) - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff
|Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff
|Complete
|
|
|
|-
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
|Disease
|
|
|
|
|
|
|
|
|
|
|FQR
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myeloid proliferations associated with Down syndrome
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
|Disease
|Disease
|
|
|
|
|
|
|
|
|
|
|FQR
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
|Disease
|Disease
|
|
|
|
|
|
|
|
|
|
|FQR
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia with KMT2A rearrangement
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|Tracy Tucker, PhD, FCCMG
|4/6/24
|
|Pending
|
|
|JH_MS
|
|
|
|
|Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1
|Tracy Tucker, PhD, FCCMG
|Complete
|
|
|-
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
|Disease
|Tracy Tucker, PhD, FCCMG
|4/6/24
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged
|Tracy Tucker, PhD, FCCMG
|Complete
|
|
|
|
|-
|-
|Acute leukaemia of ambiguous lineage with other defined genetic alterations
|[[HAEM5:Acute leukaemia of ambiguous lineage with other defined genetic alterations|Acute leukaemia of ambiguous lineage with other defined genetic alterations]]
|Disease
|Disease
|
|
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia, B/myeloid
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
|Disease
|Disease
|Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified
|Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD
|Complete
|
|
|
|
|-
|-
|Mixed-phenotype acute leukaemia, T/myeloid
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
|Disease
|Disease
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|Complete
|
|
|
|
|-
|-
|Mixed-phenotype acute leukaemia, rare types
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
|Disease
|Disease
|Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina
|PENDING
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types
|Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina
|PENDING
|
|
|
|
|-
|-
|Acute leukaemia of ambiguous lineage, NOS
|[[HAEM5:Acute leukaemia of ambiguous lineage, NOS|Acute leukaemia of ambiguous lineage, NOS]]
|Disease
|Disease
|
|
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Acute undifferentiated leukaemia
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
|Disease
|Disease
|Amelia Nakanishi, MD and Shashi Shetty, PhD
|PENDING
|
|
|
|
|
|
|
|
|Acute Undifferentiated Leukemia
|Amelia Nakanishi, MD and Shashi Shetty, PhD
|Complete
|
|
|Check reference format
|-
|-
|CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
----<br />
----<br />
----<br />
|
|
----<br />
|-
|[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]]
|Disease
|
|
|
|
|
|
|
|
|Greg Corboy (GC)
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
|Disease
|Disease
|PENDING
|
|
|
|
|
|
|
|
|
|GC
|
|
|
|
|Blastic Plasmacytoid Dendritic Cell Neoplasm
|Hao Liu, MD and Daynna J. Wolff, PhD
|Complete
|
|
|Previously within myeloid section under JH/MS editors
|-
|-
|Blastic plasmacytoid dendritic cell neoplasm
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
|Disease
|Disease
|Hao Liu, MD and Daynna J. Wolff, PhD
|PENDING
|
|
|
|
|
|
|
|GC
|
|
|
|
|Langerhans Cell Histiocytosis
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|5/19/2022<br />
|Date completed by author: 04/28/2022
|-
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]
|Disease
|PENDING
|
|
|
|
|
|
|
|
|GC
|
|
|
|
|Langerhans Cell Sarcoma
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|5/19/2022<br />
|Date completed by author: 04/28/2022
|-
|[[HAEM5:Indeterminate dendritic cell tumour|Indeterminate dendritic cell tumour]]
|Disease
|
|
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
|Disease
|
|
|
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
|Disease
|
|
|
|
|
|
|
|
|GC
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
|Disease
|
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
|Disease
|
|
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:ALK-positive histiocytosis|ALK-positive histiocytosis]]
|Disease
|
|
|
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]
|Disease
|PENDING
|
|
|
|
|
|
|
|
|GC
|
|
|
|Histiocytic Sarcoma
|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
|Complete
|10/01/2021
|Date completed by author: 10/01/2021
|-
|-
|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
----<br />
----<br />
|
|
----<br />
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
----<br />
----<br />
----<br />
|
|
----<br />
|-
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
|Disease
|
|
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
|Disease
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Unicentric Castleman disease|Unicentric Castleman disease]]
|Disease
|
|
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
|[[HAEM5:Idiopathic multicentric Castleman disease|Idiopathic multicentric Castleman disease]]
|Disease
|
|
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]
|Disease
|PENDING
|
|
|
|
|
|
|
|
|GC
|
|
|
|Multicentric Castleman Disease
|Sudha Arumugam, MD
|Complete
|01/24/2022
|Date completed by author: 01/24/2022
|-
|-
|Langerhans cell histiocytosis||Disease||Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland|| || || || ||GC||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|Disease
|PENDING
|
|
|
|
|Holli Drendel (HD)
|
|
|B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified
|Holli Drendel
|PENDING
|
|
|-
|-
|Langerhans cell sarcoma||Disease||Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland|| || || || ||GC||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|Disease
|PENDING
|
|
|
|
|HD
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|PENDING
|
|
|-
|-
|Indeterminate dendritic cell tumour||Disease|| || || || || ||GC||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|Disease
|PENDING
|
|
|
|
|HD
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy
|Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG
|Complete
|
|
|-
|-
|Interdigitating dendritic cell sarcoma||Disease|| || || || || ||GC||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|Disease
|Holli Drendel
|
|
|?Complete? Looks like tables need more editing.
|
|HD
|
|
|B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli]
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|?Complete
|
|
|-
|-
|Juvenile xanthogranuloma||Disease|| || || || || ||GC||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
|Disease
|PENDING
|
|
|
|
|HD
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|PENDING
|
|
|-
|-
|Erdheim-Chester disease||Disease|| || || || || ||GC||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|Disease
|PENDING
|
|
|
|
|HD
|
|
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
|Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine
|Complete
|
|
|-
|-
|Rosai-Dorfman Disease||Disease|| || || || || ||GC||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|Disease
|PENDING
|
|
|
|
|HD
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged
|Yassmine Akkari Nicolas Millan
|PENDING
|
|
|-
|-
|ALK-positive histiocytosis||Disease|| || || || || ||GC||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|Disease
|PENDING
|
|
|
|
|HD
|
|
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma
|PENDING
|
|
|-
|-
|Histiocytic sarcoma||Disease||Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic|| || || || ||GC||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
| ||
|Disease
|
|
|
|
|
|HD
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma||Disease|| || || || || ||GC||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|Disease
|PENDING
|
|
|
|
|HD
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|PENDING
|
|
|-
|-
|IgG4-related disease||Disease|| || || || || ||GC||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|Disease
|PENDING
|
|
|
|
|HD
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|PENDING
|
|
|-
|-
|Unicentric Castleman disease||Disease|| || || || || ||GC||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
| ||
|Disease
|
|
|
|
|
|HD
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Idiopathic multicentric Castleman disease||Disease|| || || || || ||GC||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
| ||
|Disease
|
|
|
|
|
|HD
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|KSHV/HHV8-associated multicentric Castleman disease||Disease||Sudha Arumugam, MD|| || || || ||GC||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|Disease
|
|
|
|
|
|HD
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|NEW (No Prior)
|-
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC||
|-
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC||
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC||
| ||
|-
| ||
|-
|-
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|ISSUE- FIX
Resolve Non-WHO entities
|
|
|
|
|
|
|
|
|ISSUE - FIX
|
|
|
|
|
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
| || || || ||Shivani Golem (SG)
| ||
| ||
|Monoclonal B-cell Lymphocytosis
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
|PENDING, 4/30/2024
|
|Assigned 12/19/2022 with completion date of 1/19/2023
|-
|-
| || || || || || || || ||
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa
| ||
Renee Eigsti, MD, Pathology Services of Kalamazoo
Honey Reddi, PhD, Belay Diagnostics
| || ||Complete|| ||SG|| ||
|Already converted to 5th edition
|Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD
|
|
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||
| ||
| || || || ||SG|| ||
|Hairy Cell Leukemia
|Snehal Patel, MD, PhD
|Complete
|
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||
| ||
| || || || ||SG|| ||
|Splenic Marginal Zone Lymphoma
|Snehal Patel, MD, PhD
|Complete
|
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
| ||
| || || || ||SG|| ||
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Snehal Patel, MD, PhD
|Complete
|
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
|Disease
|
|
|
|
|
|SG
|
|
|Hairy Cell Leukemia Variant
|Snehal Patel, MD, PhD
|Complete
|
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
|Disease
|PENDING
|
|
|
|
|SG
|
|
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|Complete
|4/12/2023 by FQR
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
|Disease
|PENDING
|
|
|
|
|SG
|
|
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI)
|Complete
|4/12/23 by FQR
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
| ||
|Disease
|
|
|
|
|
|SG
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
| || || || || || || || ||
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
|Disease
|PENDING
|
|
|
|
|SG
|
|
|Nodal Marginal Zone Lymphoma
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
|Complete
|5/28/2021
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]
|Disease
|PENDING
|
|
|
|
|SG
|
|
|Paediatric Nodal Marginal Zone Lymphoma
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|Complete
|11/11/2020
|
|-
|-
| || || || || || || || ||
|[[HAEM5:In situ follicular B-cell neoplasm|In situ follicular B-cell neoplasm]]
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|
|Pending
|
|SG
|
|
|In Situ Follicular Neoplasia
|Rachel D. Burnside, PhD, MBA, FACMGG
|Pending
|
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Follicular lymphoma|Follicular lymphoma]]
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|
|Pending
|
|SG
|
|Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity
|(1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma
|(1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|Pending
|
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
|Disease
|PENDING
|
|
|
|
|SG
|
|
|Paediatric-Type Follicular Lymphoma
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|Complete
|8/16/2020
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Duodenal-type follicular lymphoma|Duodenal-type follicular lymphoma]]
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|
|Pending
|
|SG
|
|
|Duodenal-Type Follicular Lymphoma
|No prior content
|
|
|
|-
|-
| || || || || || || || ||
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
| ||
|Disease
|-
|PENDING
|
|
|-
|
|
|SG
|-
|
|
|Primary Cutaneous Follicle Centre Lymphoma
|-
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
| || || || || || || || ||
|Complete
| ||
|09/10/2022
|-
|
|-
|-
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
|Disease
|PENDING
|
|
|
|
|
|SG
|
|
|
|
|In Situ Mantle Cell Neoplasia
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
|Complete
|7/26/2022
|
|
|-
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
|Disease
|PENDING
|
|
|
|
|
|
|
|
|SG
|
|
|
|
|Mantle Cell Lymphoma
|Mahsa Khanlari, MD and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|Pending
|
|
|Target completion date 8/15/20
|-
|-
| || || || || || || || ||
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
|Disease
|
|
|-
| || || || || || || || ||
|-
| || || || || || || || ||
|
|
|
|
|
|
|SG
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
|Disease
|
|
|
|
|
|
|
|
|SG
|
|
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
| || || || || || || || ||
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||PENDING
| ||
| || || || ||GC|| ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
|Pending
|
|Requested to update 14022022
|-
|-
| || || || || || || || ||
|[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||SP||
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||PENDING
| ||
| || || || ||GC|| ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|Complete
|24/02/2022
|
|-
|-
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD|| || || || ||SP||
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||PENDING
| ||
| || || || ||GC|| ||
|ALK-Positive Large B-cell Lymphoma
|Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
|Pending
|
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
|-
|-
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||PENDING
| ||
| || || || ||GC|| ||
|Large B-cell Lymphoma with IRF4 Rearrangement
|Afia Hasnain, MBBS, PhD
|Complete
|5/26/2021
|
|-
|-
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||PENDING
| ||
| || || || ||GC|| ||
|Burkitt-Like Lymphoma with 11q Aberration
|Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina
|Comlete
|27/01/2022
|
|-
|-
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
|[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor
| ||
|3/22/24|| ||Pending|| ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Lymphoplasmacytic lymphoma||Disease||Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)|| || || || ||SP||
|[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|-
|NEW (No Prior)
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue||Disease|| || || || || ||SP||
|NEW (No Prior)
| ||
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary cutaneous marginal zone lymphoma||Disease|| || || || || ||SP||
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||PENDING
| ||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Nodal marginal zone lymphoma||Disease||Andrew Ly, DO and Shivani Golem, PhD, FACMG|| || || || ||SP||
|[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Paediatric nodal marginal zone lymphoma||Disease||* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD|| || || || ||SP||
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||PENDING
| ||
| || || || ||GC|| ||
|Plasmablastic Lymphoma
|Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Complete
|28/03/2022
|
|-
|-
|In situ follicular B-cell neoplasm||Disease||Rachel D. Burnside, PhD, MBA, FACMGG|| || || || ||SP||
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||PENDING
| ||
| || || || ||GC|| ||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|(1) Pending + (2) Complete
|(1) Not ready + (2) 03/28/22
|For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022
|-
|-
|Follicular lymphoma||Disease||Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida|| || || || ||SP||
|[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Paediatric-type follicular lymphoma||Disease||*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG|| || || || ||SP||
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||PENDING
| ||
| || || || ||GC|| ||
|Intravascular Large B-cell Lymphoma
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
|Complete
|9/1/22
|Emailed 28/3/2022 for progress update
|-
|-
|Duodenal-type follicular lymphoma||Disease|| || || || || ||SP||
|[[HAEM5:Primary mediastinal large B-cell lymphoma|Primary mediastinal large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary cutaneous follicle centre lymphoma||Disease||Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG|| || || || ||SP||
|[[HAEM5:Mediastinal grey zone lymphoma|Mediastinal grey zone lymphoma]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|In situ mantle cell neoplasm||Disease||Rina Kansal, MD; Versiti Blood Center of Wisconsin|| || || || ||SP||
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||PENDING
| ||
| || || || ||GC|| ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
|Complete
|16/11/2021
|
|-
|-
|Mantle cell lymphoma||Disease||* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SP||
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||PENDING
| ||
| || || || ||GC|| ||
|Burkitt Lymphoma
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|Complete
|28/06/2021
|
|-
|-
|Leukaemic non-nodal mantle cell lymphoma||Disease||<br />|| || || || ||SP||
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Transformations of indolent B-cell lymphomas||Disease|| || || || || ||SP||
|[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Cold agglutinin disease||Disease|| || || || || ||SP||
|[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SP||
|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content. What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| ||
| ||
|
|
|
|
|
|-
|-
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SP||
|[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
| ||
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
| || || || ||GC|| ||
|Polymorphic Post-Transplant Lymphoproliferative Disorders
|Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)
|Completed
|26/4/2022
|
|-
|-
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SP||
|[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SP||
|[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
| ||
|
|
|
|
|
|-
|-
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SP||
|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| ||
| ||
|
|
|
|
|
|-
|-
|Mu heavy chain disease||Disease|| || || || || ||SP||
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||PENDING
| ||
| || || ||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
|Pending + Completed (03/21/22)
|Not completed for checking (1, 3 and 4) + 03/21/22 (2)
|
|-
|-
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA|| || || || ||SP||
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease|| || || || || ||GC|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Alpha heavy chain disease||Disease|| || || || || ||SP||
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]]
| ||
|Disease
|
|
|
|
|
|SG
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Plasmacytoma||Disease|| || || || || ||SP||
|[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SP||
|[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD|| || || || ||SP||
|[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Kikuchi-Fujimoto disease||Disease|| || || || || ||SP||
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||PENDING
| || || || ||SG
| ||
| ||
|Primary Amyloidosis
|Heather E. Williams, PhD, MS, PgD, ErCLG
|?PENDING<br />
|
|
|-
|-
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SP||
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||PENDING
| || || || ||SG
| ||
| ||
|Light Chain and Heavy Chain Deposition Disease
|Chen Yang, MD, PhD, University of Michigan
|Complete
|10/15/2022
|
|-
|-
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SP||
|[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|T-prolymphocytic leukaemia||Disease|| || || || || ||SP||
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||PENDING
| || || || ||SG
| ||
| ||
|Gamma Heavy Chain Disease
|Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA
|Complete
|5/26/2021
|
|-
|-
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SP||
|[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SP||
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||PENDING
| ||
| || || ||
|SG
| ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center|| || || || ||SP||
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||PENDING
| ||
| || || || ||SG
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
|Pending
|
|
|-
|-
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SP||
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
| ||
| || || ||
|SG
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
|(1) POEMS Syndrome + (2) TEMPI Syndrome
|(1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD
|?PENDING
|
|
|-
|-
|Disease (5th Edition)
| ||
|Page Type
|Author (5th Edition) (Note: please indicate trainees in parenthesis)
|Date Assigned to Author (5th Edition)
|Target Completion Date (5th Edition)
|Content Status (5th Edition) (Pending or Complete)
|Date Completed by Author (5th Edition)
|Associate Editor
|Date of Last Editor Review (5th Edition)
|Notes (5th Edition)
|Correlated Prior Disease Name (4th Edition)
|Correlated Prior Author (4th Edition)
|Prior Content Status (4th Edition) (Pending or Complete)
|Prior Date of Last Editor Review (4th Edition)
|Prior Notes (4th Edition)
|-
|-
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SP||
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SP||
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK)
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SP||
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD
| ||
|3/25/2024
| || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SP||
|[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SP||
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SP||
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
|Disease
|Fei Yang, MD
|
|
|Pending
|
|SK
|
|
|Early T-Cell Precursor Lymphoblastic Leukemia
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|Pending
|
|
|-
|-
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SP||
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
| ||
|Disease
|Parastou Tizro, MD (trainee);
Sumire Kitahara, MD
|3/17/2024
|
|Pending
|
|SK
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SP||
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS
| ||
|3/17/2024
|6/30/24
|Pending
| ||SK|| ||
|T-cell Large Granular Lymphocytic Leukemia
|Michelle Don, MD, MS
|Pending
|
|
|-
|-
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SP||
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
| ||
Michelle Don, MD, MS
|3/17/2024
|6/30/24
|Pending
| ||SK|| ||
|Chronic Lymphoproliferative Disorder of NK Cells
|Michelle Don, MD
|Pending
|
|
|-
|-
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SP||
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||
| ||
| || || || ||SK|| ||
|Adult T-cell Leukemia/Lymphoma
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center
|?Pending
|
|
|-
|-
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SP||
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
| ||
|3/22/2024
| || || ||SK|| ||
|Sézary Syndrome
|Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina
|Pending
|
|
|-
|-
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SP||
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||PENDING
| ||
| || || || ||SK|| ||
|Aggressive NK-cell Leukemia
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|?Pending
|
|
|-
|-
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SP||
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc
| ||
|3/19/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SP||
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee),
| ||
Andrew Siref, MD
|4/12/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SP||
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
| ||
|3/22/2024
| || || ||SK|| ||
|Mycosis Fungoides
|Jane Scribner, MD and Daynna J. Wolff, PhD
|Pending
|
|
|-
|-
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SP||
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease|| || || || || ||SK|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA|| || || || ||SP||
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||PENDING
| ||
| || || || ||SK|| ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|Theresa Spivey, MD, Shashirekha Shetty, PhD
|Pending
|
|
|-
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center|| || || || ||SP||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
| ||
|3/19/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SP||
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD
| ||
| || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SP||
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee),
| ||
Andrew Siref, MD
|4/12/2024|| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD|| || || || ||SP||
|[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SP||
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
| ||
| || || || ||SK|| ||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|-
|-
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SP||
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SP||
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
| ||
Andrew Siref, MD
|3/20/2024
| ||Pending|| ||SK|| ||
|Enteropathy-Associated T-cell Lymphoma
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
|Complete
|1/21/2021
|
|-
|-
|Severe mosquito bite allergy||Disease|| || || || || ||SP||
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
| ||
Andrew Siref, MD
|3/20/2024
| ||Pending|| ||SK|| ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|-
|-
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SP||
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
| ||
| || || || ||SK|| ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
|Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA)
|Complete
|9/26/2022
|
|-
|-
|Systemic chronic active EBV disease||Disease|| || || || || ||SP||
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
| ||
Michelle Don, MD, MS
|3/19/2024
|6/30/24
|Pending
| ||SK|| ||
|Hepatosplenic T-cell Lymphoma
|Michelle Don, MD, MS
|Complete
|1/21/2021
|
|-
|-
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SP||
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
| ||
Sumire Kitahara, MD
| || ||Pending
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Positive
|Miguel Gonzalez Mancera, MD
Sumire Kitahara, MD
Cedars-Sinai, Los Angeles, CA
|Complete
|09/23/2022
|
|-
|-
|Follicular dendritic cell sarcoma||Disease||Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG|| || || || ||SP||
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
| ||
Sumire Kitahara, MD
| || ||Pending
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Negative
|Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA
|Complete
|09/23/2022
|
|-
|-
|EBV-positive inflammatory follicular dendritic cell sarcoma||Disease|| || || || || ||SP||
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
| ||
|4/1/2024
| ||Pending|| ||SK|| ||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center
|Pending
|
|
|-
|-
|Fibroblastic reticular cell tumour||Disease|| || || || || ||SP||
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
| ||
| ||Pending|| ||SK|| ||prior authors not available
|Angioimmunoblastic T-cell Lymphoma
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
|Pending
|
|
|-
|-
|Intranodal palisaded myofibroblastoma||Disease|| || || || || ||SP||
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
| ||
| ||Pending|| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Littoral cell angioma||Disease|| || || || || ||SP||
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
| ||
| || || || ||SK|| ||
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
|Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD
|Pending
|
|
|-
|-
|Splenic hamartoma||Disease|| || || || || ||SP||
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
| ||
|6/25/2023
| || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Sclerosing angiomatoid nodular transformation (SANT) of spleen||Disease|| || || || || ||SP||
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B-lymphoblastic leukaemia/lymphoma||Disease|| || || || || ||YA||
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc
| ||
|3/19/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy||Disease||Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG|| || || || ||YA||
|[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B-lymphoblastic leukaemia/lymphoma with hypodiploidy||Disease||Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG|| || || || ||YA||
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B-lymphoblastic leukaemia/lymphoma with iAMP21||Disease||Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte|| || || || ||YA||
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
| ||
|3/25/2024
| || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion||Disease||Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG|| || || || ||YA||
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
| ||
|3/25/2024
| || || ||SK|| ||prior authors not available
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
|Complete
|11/21/2021
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features||Disease||Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine|| || || || ||YA||
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement||Disease||Yassmine Akkari Nicolas Millan|| || || || ||YA||
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
|Disease
|PENDING
|
|
|
|
|GC
|
|
|Follicular Dendritic Cell Sarcoma
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|?Pending
|
|
|-
|-
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion||Disease||Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma|| || || || ||YA||
|[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]]
| ||
|Disease
|
|
|
|
|
|GC
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features||Disease|| || || || || ||YA||
|[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]]
| ||
|Disease
|
|
|
|
|
|GC
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion||Disease||Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO|| || || || ||YA||
|[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]]
| ||
|Disease
|
|
|
|
|
|GC
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion||Disease||Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO|| || || || ||YA||
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
| ||
|Disease
|
|
|
|
|
|GC
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion||Disease|| || || || || ||YA||
|[[HAEM5:Splenic hamartoma|Splenic hamartoma]]
| ||
|Disease
|
|
|
|
|
|GC
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations||Disease|| || || || || ||YA||
|[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]]
| ||
|Disease
|
|
|
|
|
|GC
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B-lymphoblastic leukaemia/lymphoma, NOS||Disease|| || || || || ||YA||
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|-
|-
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||YA||
|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease|| || || || || ||NA|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Early T-precursor lymphoblastic leukaemia / lymphoma||Disease||Fei Yang, MD, FACMG, Kaiser Permanente Northwest|| || || || ||YA||
|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease|| || || || || ||NA|| ||
| ||
|NEW (No Prior)
|-
|NEW (No Prior)
|Fanconi anaemia||Disease|| || || || || ||NA||
|NEW (No Prior)
| ||
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Bloom syndrome||Disease|| || || || || ||NA||
|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease|| || || || || ||NA|| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA||
|[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| ||
| ||
|NEW (No Prior)
|-
|NEW (No Prior)
|RASopathies||Disease|| || || || || ||NA||
|NEW (No Prior)
| ||
|NEW (No Prior)
|NEW (No Prior)
|}
|}